Advertisement

Topics

PARP Inhibitors in Oncology [Report Updated: 18092018] Prices from USD $6796

20:34 EST 4 Dec 2018 | BioPortfolio Reports

PARP Inhibitors in Oncology


Summary


Since hitting the market in 2015, drugs that target poly ADPribose polymerase PARP have transformed the clinical management of cancers harboring BRCAmutations. As more PARP inhibitors have been commercialized, drug developers are turning their attention towards broadening drug labels and exploring combination strategies. This report covers the management of PARP inhibitors in the US, Europe, and Asia, focusing on efficacy and safety comparisons for approved products, current and future indications, and research and development strategies.


Scope


This report combines key opinion leader insight with inhouse analyst expertise and research to provide an insightrich look at PARP inhibitors in the US, Europe, and Asia. Components of the report include

Overview of PARP Inhibitors in Oncology: Background, mechanism of action, and clinical development of PARP inhibitors.

Epidemiology Analysis: Which current and future disease spaces are relevant to PARP inhibitors.

Marketed PARP Inhibitors: How the currently approved PARP inhibitors compare.

Pipeline Assessment in the 8MM: What are the pipeline PARP inhibitor products in development in oncology.

Key Players: What companies are developing PARP inhibitors in oncology.

Research and Development Strategies: How are PARP inhibitor clinical trials being designed, and what combination strategies are being explored in the US, Europe, and Asia.

Pricing, Reimbursement, and Regulatory Strategies: What current and future challenges face PARP inhibitors from a payer's perspective.


Reasons to buy


Develop business strategies by understanding the trends shaping and driving the PARP inhibitor market in the US, Europe, and Asia.

Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the portfolios of various competitors.

Identify areas of unmet need within the PARP inhibitor market to help drive research and development towards future market opportunities.

Gain insights to help plan and design your clinical trials.

Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments, and strategic partnerships.

Identify key pricing and reimbursement strategies.

Original Article: PARP Inhibitors in Oncology [Report Updated: 18092018] Prices from USD $6796

NEXT ARTICLE

More From BioPortfolio on "PARP Inhibitors in Oncology [Report Updated: 18092018] Prices from USD $6796"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Cancer
  Bladder Cancer Brain Cancer Breast Cancer Cancer Cervical Cancer Colorectal Head & Neck Cancers Hodgkin Lymphoma Leukemia Lung Cancer Melanoma Myeloma Ovarian Cancer Pancreatic Cancer ...

Polymerase Chain Reaction (PCR)
PCR (Polymerase Chain Reaction) uses the ability of DNA polymerase (enzymes that create DNA molecules by assembling nucleotides, the building blocks of DNA. These enzymes are essential to DNA replication and usually work in pairs to create two ident...

Pharmacy
Pharmacy is the science and technique of preparing as well as dispensing drugs and medicines. It is a health profession that links health sciences with chemical sciences and aims to ensure the safe and effective use of pharmaceutical drugs. The scope of...